| 1 | alzheimer’s disease autism spectrum | | | | | | | 5 | 0.70% |
| 2 | adhd alzheimer’s disease autism | | | | | | | 5 | 0.70% |
| 3 | cognitive function depression down’s | | | | | | | 5 | 0.70% |
| 4 | core cognitive function depression | | | | | | | 5 | 0.70% |
| 5 | liability epilepsy huntington’s disease | | | | | | | 5 | 0.70% |
| 6 | disease schizophrenia strokecerebrovascular disease | | | | | | | 4 | 0.56% |
| 7 | disorders obsessive compulsive disorder | | | | | | | 4 | 0.56% |
| 8 | epilepsy huntington’s disease multiple | | | | | | | 4 | 0.56% |
| 9 | safety core cognitive function | | | | | | | 4 | 0.56% |
| 10 | neuromuscular disorders obsessive compulsive | | | | | | | 4 | 0.56% |
| 11 | disease autism spectrum disorder | | | | | | | 3 | 0.42% |
| 12 | assessments cantab® space electronic | | | | | | | 3 | 0.42% |
| 13 | kit™ space decentralised clinical | | | | | | | 3 | 0.42% |
| 14 | space decentralised clinical trials | | | | | | | 3 | 0.42% |
| 15 | centre space contact us | | | | | | | 3 | 0.42% |
| 16 | investor centre space contact | | | | | | | 3 | 0.42% |
| 17 | down’s syndrome drug abuse | | | | | | | 3 | 0.42% |
| 18 | depression down’s syndrome drug | | | | | | | 3 | 0.42% |
| 19 | autism spectrum disorder cognitive | | | | | | | 3 | 0.42% |
| 20 | ratings quality assurance aqua | | | | | | | 3 | 0.42% |
| 21 | managementreporting space for academic | | | | | | | 3 | 0.42% |
| 22 | emotionsocial cognition executive function | | | | | | | 3 | 0.42% |
| 23 | development study design patient | | | | | | | 3 | 0.42% |
| 24 | study design patient experience | | | | | | | 3 | 0.42% |
| 25 | quality assurance aqua our | | | | | | | 3 | 0.42% |
| 26 | data managementreporting space for | | | | | | | 3 | 0.42% |
| 27 | assurance aqua our science | | | | | | | 3 | 0.42% |
| 28 | technologydelivery support our technologies | | | | | | | 3 | 0.42% |
| 29 | function depression down’s syndrome | | | | | | | 3 | 0.42% |
| 30 | injury menu toggle | | | | | | 2 | 0.28% |
| 31 | area adhd alzheimer’s disease | | | | | | | 2 | 0.28% |
| 32 | decentralised clinical trials clinpal | | | | | | | 2 | 0.28% |
| 33 | menu toggle by | | | | | | 2 | 0.28% |
| 34 | menu toggle by cognitive | | | | | | 2 | 0.28% |
| 35 | aqua our science menu | | | | | | 2 | 0.28% |
| 36 | clinical trials clinpal econsent | | | | | | | 2 | 0.28% |
| 37 | cognition kit™ space decentralised | | | | | | | 2 | 0.28% |
| 38 | toggle by cognitive function | | | | | | | 2 | 0.28% |
| 39 | by cognitive function attentionpsychomotor | | | | | | | 2 | 0.28% |
| 40 | cognitive function attentionpsychomotor speed | | | | | | | 2 | 0.28% |